Expansion Opportunity Clean Cells is rapidly expanding its capacity and capabilities through strategic acquisitions (Xegen, Anaquant, Stem Genomics) and a new large cGMP facility, indicating increased demand and a need for additional quality control, analytical, and bioinformatics support services. Sales opportunities exist in supplying advanced QC assays, analytical method development, and viral testing capabilities to scale with growth.

Bioinformatics Tie-in The recent acquisition of Xegen and the appointment of Dr Julien Paganini to lead bioinformatics and analytical methods development highlight a growing emphasis on sequencing-based analysis and NGS data. This opens opportunities to offer integrated bioinformatics consulting, data analysis, and informatics-enabled QC solutions for viral vectors and cell therapies.

Virus-Based Expertise As a GMP-focused CDMO with sister company Naobios and experience in virus-based product development, Clean Cells can be a partner for biopharma companies aiming to develop or manufacture viral vectors or virus-based modalities, presenting cross-sell opportunities for process development, manufacturing, and quality control testing.

Strategic Geography A major French facility expansion positions Clean Cells as a European hub for biopharmaceutical QC and cell bank production. There is potential to win European market share from mid-sized biotechs and contract manufacturing organizations by offering end-to-end QC, cell banking, and analytical services at scale.

Integrated Services With capabilities spanning R&D, GMP production, QC testing, and bespoke assays across BSL2 and BSL3, Clean Cells can package bundled service offerings for biotech clients, including development, manufacturing, testing, and regulatory-compliant analytics, enabling higher contract value and longer engagement cycles.